[Use of nabumetone in the treatment of primary dysmenorrhea. Report of 100 cases].
The aim of the study was to assess the efficacy and tolerability of nabumetone, a new nonsteroid anti-inflammatory agent with analgesic and antipyretic functions, in the treatment of primary dysmenorrhea in 100 patients. Treatment was administered at a dose of 1 g per day for slight and moderate cases and 2 g per day for severe forms, starting from the onset of painful symptoms and lasting while they persisted. Side effects were observed in 7% of cases but were limited to the gastroenteric tract. The analysis of results confirms that with regard to the remission of symptoms, treatment was efficacious from the second month and that a further improvement was obtained with continued treatment. However, the Authors observed that, although the remission of symptoms was partial in the majority of cases, there was a greater response in cases of moderate or severe dysmenorrhea and their duration was shorter in comparison to those months in which patients had not received nabumetone treatment.
Bottino
G
G
Reparto di Ostetricia e Ginecologia, USSL n. 35, Ospedale Civile di Giaveno, Torino.
Menna
C
C
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002074:Butanones / Q000627:therapeutic use*; D004341:Drug Evaluation; D004412:Dysmenorrhea / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D000077430:Nabumetone
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D000077430:Nabumetone
Impiego di nabumetone nel trattamento della dismenorrea primaria. Descrizione di 100 casi.